At the conclusion of this conference, participants should be able to:
1.  Identify updates in molecular abnormalities which can be utilized in the diagnosis, prognosis, risk stratification
and therapy selection for patients with myeloid malignancies.
2.  Discuss and assess the relevant clinical trial data in clinical practice which has the potential to improve
outcomes in patients with malignant hematologic disorders including Non-Hodgkin's Lymphoma, CLL, and
Multiple Myeloma
3.   Review the updates in sequencing strategies in the era of novel immunotherapies, CAR-T, targeted therapies
and stem cell transplantation
4.  Discuss the latest advances in coagulation and platelet disorders